Nectar Lifesciences (NSE:NECLIFE) Total Equity: ₹5,823 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
52 GF Score
Price ₹10.85
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences Total Equity?

Nectar Lifesciences NSE:NECLIFE -0.46% 52 Total Equity is ₹5,823 Mil as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 52/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Nectar Lifesciences's total equity for the quarter that ended in Mar. 2026 was ₹5,823 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nectar Lifesciences Total Equity Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Total Equity Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,879.04 10,645.94 10,692.54 9,561.13 5,822.95

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,561.13 0.00 7,168.70 0.00 5,822.95
NSE:NECLIFE
52GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nectar Lifesciences's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=6216.064-393.11
=5,823

Nectar Lifesciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=6216.064-393.11
=5,823

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹5,823 Mil mean?
Nectar Lifesciences (NSE:NECLIFE) has a Total Equity of ₹5,823 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' Total Equity too high?
Nectar Lifesciences' current Total Equity is ₹5,823 Mil. Overall, Nectar Lifesciences has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Total Equity compare to ZTS and UTHR?
Nectar Lifesciences' Total Equity of ₹5,823 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nectar Lifesciences and its competitors. Nectar Lifesciences's current Total Equity is ₹5,823 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹10.85 — trading 58.2% above its estimated fair value. The current Total Equity is ₹5,823 Mil. Nectar Lifesciences' overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Total Equity is ₹5,823 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹10.85 is trading 58.2% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Total Equity: ₹5,823 Mil
  • GF Value™: ₹6.86 vs. price of ₹10.85 (58.2% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
52GF Score

Get the complete analysis for NSE:NECLIFE

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.85
Price
₹6.86
GF Value